GILEAD SCIENCES, INC.
GILDAPI behind this page
GILD FY 2025 request
Playground key active
/api/financials?ticker=GILD&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 29,443 | 28,754 | +2.4% |
Show Product Lines breakouts |
|||
| AmBisome | 509 | 533 | -4.5% |
| AmBisome · Europe | 267 | 276 | -3.3% |
| AmBisome · Rest of World | 221 | 212 | +4.2% |
| AmBisome · US | 20 | 44 | -54.5% |
| Biktarvy | 14,334 | 13,423 | +6.8% |
| Biktarvy · Europe | 1,676 | 1,509 | +11.1% |
| Biktarvy · Rest of World | 1,190 | 1,060 | +12.3% |
| Biktarvy · US | 11,467 | 10,855 | +5.6% |
| Descovy | 2,758 | 2,113 | +30.5% |
| Descovy · Europe | 93 | 100 | -7.0% |
| Descovy · Rest of World | 105 | 110 | -4.5% |
| Descovy · US | 2,559 | 1,902 | +34.5% |
| Genvoya | 1,498 | 1,762 | -15.0% |
| Genvoya · Europe | 148 | 180 | -17.8% |
| Genvoya · Rest of World | 69 | 84 | -17.9% |
| Genvoya · US | 1,281 | 1,498 | -14.5% |
| Odefsey | 1,167 | 1,288 | -9.4% |
| Odefsey · Europe | 246 | 290 | -15.2% |
| Odefsey · Rest of World | 40 | 41 | -2.4% |
| Odefsey · US | 881 | 957 | -7.9% |
| Other | 290 | 356 | -18.5% |
| Other HIV | 500 | 434 | +15.2% |
| Other HIV · Europe | 109 | 129 | -15.5% |
| Other HIV · Rest of World | 40 | 48 | -16.7% |
| Other HIV · US | 352 | 257 | +37.0% |
| Other Liver Disease | 874 | 467 | +87.2% |
| Other Liver Disease · Europe | 330 | 202 | +63.4% |
| Other Liver Disease · Rest of World | 69 | 73 | -5.5% |
| Other Liver Disease · US | 476 | 192 | +147.9% |
| Other · Europe | 32 | 34 | -5.9% |
| Other · Rest of World | 81 | 68 | +19.1% |
| Other · US | 177 | 255 | -30.6% |
| Product | 28,915 | 28,610 | +1.1% |
| Product · Europe | 4,617 | 4,576 | +0.9% |
| Product · Rest of World | 3,483 | 3,526 | -1.2% |
| Product · US | 20,816 | 20,508 | +1.5% |
| Royalty, contract and other revenues | 527 | 144 | +266.0% |
| Royalty, contract and other revenues · Europe | 447 | 58 | +670.7% |
| Royalty, contract and other revenues · Rest of World | 20 | 4 | +400.0% |
| Royalty, contract and other revenues · US | 60 | 82 | -26.8% |
| Sofosbuvir/Velpatasvir | 1,272 | 1,596 | -20.3% |
| Sofosbuvir/Velpatasvir · Europe | 292 | 299 | -2.3% |
| Sofosbuvir/Velpatasvir · Rest of World | 344 | 374 | -8.0% |
| Sofosbuvir/Velpatasvir · US | 636 | 922 | -31.0% |
| Symtuza - Revenue share | 495 | 592 | -16.4% |
| Symtuza - Revenue share · Europe | 120 | 130 | -7.7% |
| Symtuza - Revenue share · Rest of World | 12 | 12 | 0.0% |
| Symtuza - Revenue share · US | 363 | 450 | -19.3% |
| Tecartus | 344 | 403 | -14.6% |
| Tecartus · Europe | 158 | 138 | +14.5% |
| Tecartus · Rest of World | 32 | 31 | +3.2% |
| Tecartus · US | 153 | 234 | -34.6% |
| Total Cell Therapy | 1,839 | 1,973 | -6.8% |
| Total Cell Therapy · Europe | 755 | 804 | -6.1% |
| Total Cell Therapy · Rest of World | 335 | 274 | +22.3% |
| Total Cell Therapy · US | 748 | 896 | -16.5% |
| Total HIV | 20,752 | 19,612 | +5.8% |
| Total HIV · Europe | 2,392 | 2,339 | +2.3% |
| Total HIV · Rest of World | 1,456 | 1,355 | +7.5% |
| Total HIV · US | 16,904 | 15,918 | +6.2% |
| Total Liver Disease | 3,217 | 3,021 | +6.5% |
| Total Liver Disease · Europe | 671 | 545 | +23.1% |
| Total Liver Disease · Rest of World | 927 | 876 | +5.8% |
| Total Liver Disease · US | 1,619 | 1,601 | +1.1% |
| Total Oncology | 3,236 | 3,289 | -1.6% |
| Total Oncology · Europe | 1,102 | 1,098 | +0.4% |
| Total Oncology · Rest of World | 508 | 393 | +29.3% |
| Total Oncology · US | 1,626 | 1,798 | -9.6% |
| Total Other | 799 | 889 | -10.1% |
| Total Other · Europe | 300 | 310 | -3.2% |
| Total Other · Rest of World | 302 | 280 | +7.9% |
| Total Other · US | 197 | 299 | -34.1% |
| Trodelvy | 1,397 | 1,315 | +6.2% |
| Trodelvy · Europe | 347 | 294 | +18.0% |
| Trodelvy · Rest of World | 173 | 119 | +45.4% |
| Trodelvy · US | 877 | 902 | -2.8% |
| Veklury | 911 | 1,799 | -49.4% |
| Veklury · Europe | 151 | 284 | -46.8% |
| Veklury · Rest of World | 290 | 623 | -53.5% |
| Veklury · US | 470 | 892 | -47.3% |
| Vemlidy | 1,070 | 959 | +11.6% |
| Vemlidy · Europe | 49 | 44 | +11.4% |
| Vemlidy · Rest of World | 514 | 428 | +20.1% |
| Vemlidy · US | 507 | 486 | +4.3% |
| Yescarta | 1,495 | 1,570 | -4.8% |
| Yescarta · Europe | 598 | 666 | -10.2% |
| Yescarta · Rest of World | 303 | 242 | +25.2% |
| Yescarta · US | 595 | 662 | -10.1% |
Show Geography breakouts |
|||
| Europe | 5,064 | 4,634 | +9.3% |
| Rest of World | 3,503 | 3,529 | -0.7% |
| US | 20,876 | 20,591 | +1.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -5 | 27 | -118.5% |
Show Type Of Arrangement breakouts |
|||
| Janssen pharmaceuticals | 1.3 | 1.4 | -7.1% |
| Shionogi, formerly Japan Tobacco | 1.6 | 1.8 | -11.1% |
| Cost of Revenue | 6,234 | 6,251 | -0.3% |
Show Type Of Arrangement breakouts |
|||
| Janssen pharmaceuticals | 369 | 403 | -8.4% |
| Research And Development Expense Excluding Acquired In Process Cost | 5,799 | 5,907 | -1.8% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Arcus · Arcus collaboration agreement | 218 | 243 | -10.3% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 1,024 | 4,663 | -78.0% |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 590 | 4,180 | -85.9% |
Show Indefinite Lived Intangible Assets By Major Class breakouts |
|||
| In Process Research And Development Bulevirtide | 590 | — | — |
| Selling, General & Administrative | 5,774 | 6,091 | -5.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 5,774 | 6,091 | -5.2% |
Show Counterparty Name breakouts |
|||
| Gilead Foundation · Related Party | 89 | — | — |
| Total Costs & Expenses | 19,421 | 27,092 | -28.3% |
| Operating Income | 10,022 | 1,662 | +503.0% |
| Interest Expense | 1,024 | 977 | +4.8% |
| Non-Operating Income (Expense) | -798 | -6 | -13200.0% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | 5 | -120.0% |
| Income Before Taxes | 9,796 | 690 | +1319.7% |
| Income Tax Expense (Benefit) | 1,286 | 211 | +509.5% |
Show Equity Components breakouts |
|||
| Income tax (benefit) expense · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | 3 | -133.3% |
| Net Income | 8,510 | 480 | +1672.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 8,510 | 480 | +1672.9% |
| Net Income | 8,510 | 480 | +1672.9% |
| EPS (Basic) | 6.84 | 0.38 | +1700.0% |
| EPS (Diluted) | 6.78 | 0.38 | +1684.2% |
| Wtd Avg Shares (Basic) | 1,244 | 1,247 | -0.2% |
| Wtd Avg Shares (Diluted) | 1,255 | 1,255 | 0.0% |
| Sales & Marketing (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 3,522 | 3,453 | +2.0% |
| General & Administrative (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,252 | 2,638 | -14.6% |
| Other Non-Operating Income (Expense) | 1 | 2 | -50.0% |
| Comprehensive Income | 8,418 | 584 | +1341.4% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -139 | 125 | -211.2% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 7,564 | 9,991 | -24.3% |
| Marketable Securities (Current) | 68 | — | — |
| Accounts Receivable | 4,913 | 4,420 | +11.2% |
| Inventory | 1,774 | 1,710 | +3.7% |
Show Public Utilities Inventory breakouts |
|||
| Trodelvy | 613 | — | — |
| Prepaid Expenses & Other Current Assets | 4,024 | 3,052 | +31.8% |
| Total Current Assets | 18,342 | 19,173 | -4.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 5,606 | 5,414 | +3.5% |
Show Geography breakouts |
|||
| Non Us | 631 | 627 | +0.6% |
| US | 4,975 | 4,787 | +3.9% |
| Marketable Securities (Non-Current) | 2,974 | — | — |
| Goodwill | 8,314 | 8,314 | 0.0% |
| Deferred Tax Assets | 1,964 | 2,378 | -17.4% |
| Other Non-Current Assets | 4,845 | 3,769 | +28.5% |
| Total Assets | 59,023 | 58,995 | 0.0% |
| Operating Lease Right-of-Use Assets | 532 | 515 | +3.3% |
| Intangible Assets | 14,678 | 17,058 | -14.0% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Hepcludex [Member] | 430 | 516 | -16.7% |
| Intangible asset – axicabtagene ciloleucel | 3,983 | 4,389 | -9.3% |
| Intangible asset – sofosbuvir | 2,272 | 2,971 | -23.5% |
| Other Intangible Assets | 428 | 535 | -20.0% |
| Trodelvy | 7,566 | 8,647 | -12.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 16,978 | 19,948 | -14.9% |
| Current Liabilities | |||
| Accounts Payable | 715 | 833 | -14.2% |
| Accrued Rebates | 4,337 | 3,892 | +11.4% |
| Debt Current | 2,807 | 1,815 | +54.7% |
| Other Liabilities Current | 3,953 | 5,464 | -27.7% |
| Total Current Liabilities | 11,813 | 12,004 | -1.6% |
| Current Portion of Long-Term Debt | 2,807 | 1,815 | +54.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 22,129 | 24,896 | -11.1% |
| Accrued Income Taxes Noncurrent | 896 | 830 | +8.0% |
| Deferred Tax Liabilities | 402 | 724 | -44.5% |
| Other Non-Current Liabilities | 1,165 | 1,295 | -10.0% |
| Long-Term Debt | 24,937 | 26,710 | -6.6% |
Show Debt Instrument breakouts |
|||
| 1.20% Senior Unsecured Notes Due October 2027 · Senior Notes | 749 | 748 | +0.1% |
| 1.65% Senior Unsecured Notes Due October 2030 · Senior Notes | 996 | 995 | +0.1% |
| 2.60% Senior Unsecured Notes Due October 2040 · Senior Notes | 990 | 989 | +0.1% |
| 2.80% Senior Unsecured Notes Due October 2050 · Senior Notes | 1,480 | 1,479 | +0.1% |
| 2.95% Senior Unsecured Notes Due in March 2027 · Senior Notes | 1,249 | 1,249 | 0.0% |
| 3.65% Senior Unsecured Notes Due in March 2026 · Senior Notes | 2,750 | 2,747 | +0.1% |
| 4.00% Senior Unsecured Notes Due in September 2036 · Senior Notes | 744 | 744 | 0.0% |
| 4.15% Senior Unsecured Notes Due in March 2047 · Senior Notes | 1,731 | 1,730 | +0.1% |
| 4.50% Senior Unsecured Notes Due in February 2045 · Senior Notes | 1,736 | 1,735 | +0.1% |
| 4.60% Senior Unsecured Notes Due in September 2035 · Senior Notes | 994 | 994 | 0.0% |
| 4.75% Senior Unsecured Notes Due in March 2046 · Senior Notes | 2,225 | 2,224 | 0.0% |
| 4.80% Senior Unsecured Notes Due in April 2044 · Senior Notes | 1,738 | 1,738 | 0.0% |
| 4.80% Senior Unsecured Notes Due in November 2029 · Senior Notes | 747 | 746 | +0.1% |
| 5.10% Senior Unsecured Notes Due in June 2035 · Senior Notes | 992 | 991 | +0.1% |
| 5.25% Senior Unsecured Notes Due October 2033 · Senior Notes | 994 | 993 | +0.1% |
| 5.50% Senior Unsecured Notes Due November 2054 · Senior Notes | 989 | 989 | 0.0% |
| 5.55% Senior Unsecured Notes Due October 2053 · Senior Notes | 989 | 988 | +0.1% |
| 5.60% Senior Unsecured Notes Due November 2064 · Senior Notes | 739 | 738 | +0.1% |
| 5.65% Senior Unsecured Notes Due in December 2041 · Senior Notes | 997 | 997 | 0.0% |
Show Long-Term Debt Type breakouts |
|||
| Notes Payable Other Payables | 1,110 | 1,148 | -3.3% |
| Senior Notes | 24,000 | — | — |
| Operating Lease Liabilities | 503 | 498 | +1.0% |
| Stockholders' Equity | |||
| Common Stock | 1 | 1 | 0.0% |
| Additional Paid-In Capital | 8,932 | 7,700 | +16.0% |
| Accumulated Other Comprehensive Income | 39 | 132 | -70.5% |
| Retained Earnings | 13,730 | 11,497 | +19.4% |
| Total Stockholders' Equity | 22,703 | 19,330 | +17.4% |
| Minority Interest | -84 | -84 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22,618 | 19,246 | +17.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -43 | 96 | -144.8% |
| Accumulated Net Unrealized Investment Gain Loss | 8 | — | — |
| Accumulated Other Comprehensive Income | 39 | 132 | -70.5% |
| Accumulated Translation Adjustment | 74 | 36 | +105.6% |
| Additional Paid In Capital | 8,932 | 7,700 | +16.0% |
| Common Stock | 1 | 1 | 0.0% |
| Noncontrolling Interest | -84 | -84 | 0.0% |
| Retained Earnings | 13,730 | 11,497 | +19.4% |
| Total Liabilities & Equity | 59,023 | 58,995 | 0.0% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 370 | 381 | -2.9% |
| Adjustment For Amortization | 2,390 | 2,386 | +0.2% |
| Stock-Based Compensation | 894 | 835 | +7.1% |
| Deferred Income Taxes | 160 | -1,844 | +108.7% |
| Increase Decrease In Equity Securities Fv Ni | -451 | 274 | -264.6% |
| Other Non-Cash Items | 480 | 353 | +36.0% |
| Change in Accounts Receivable | -367 | 139 | -364.0% |
| Change in Inventory | -1,036 | -426 | -143.2% |
| Change in Prepaid & Other Assets | -311 | -259 | -20.1% |
| Change in Accounts Payable | -132 | 290 | -145.5% |
| Increase Decrease In Income Taxes | -2,108 | -732 | -188.0% |
| Increase Decrease In Accrued Liabilities | 6 | 108 | -94.4% |
| Net Cash from Operations | 10,019 | 10,828 | -7.5% |
| Investing Activities | |||
| Purchases of Investments | -3,939 | -244 | -1514.3% |
| Proceeds From Sale Of Available For Sale Securities Debt | 854 | 2,265 | -62.3% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 55 | 327 | -83.2% |
| Payments To Acquire Businesses Net Of Cash Acquired | -1,070 | -4,840 | +77.9% |
| Payments To Acquire Other Investments | -133 | -492 | +73.0% |
| Capital Expenditures | -563 | -523 | -7.6% |
| Other Investing Activities | 2 | 58 | -96.6% |
| Net Cash from Investing | -4,793 | -3,449 | -39.0% |
| Financing Activities | |||
| Proceeds From Issuance Of Common Stock | 408 | 422 | -3.3% |
| Share Repurchases | -1,922 | -1,150 | -67.1% |
| Debt Repayments | -1,788 | -1,970 | +9.2% |
| Payments Of Dividends | -4,003 | -3,918 | -2.2% |
| Proceeds From Payments For Other Financing Activities | -440 | -281 | -56.6% |
| Net Cash from Financing | -7,745 | -3,433 | -125.6% |
| Supplemental | |||
| Income Taxes Paid | 3,215 | 2,779 | +15.7% |
| Interest Paid | 1,036 | 951 | +8.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 92 | -40 | +330.0% |
| Net Change in Cash | -2,428 | 3,906 | -162.2% |
Values in millions USD. Source: SEC EDGAR 10-K filing.